Madrigal Pharma (MDGL) Tops Q1 EPS by 54c

Madrigal Pharma (NASDAQ: MDGL) reported Q1 EPS of ($3.32), $0.54 better than the analyst estimate of ($3.86). Revenue for the quarter came in at $137.25 million versus the consensus estimate of $112.54 million.

For earnings history and earnings-related data on Madrigal Pharma (MDGL) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Robinhood Markets (HOOD) PT Raised to $130 at Cantor Fitzgerald
• Texas AG Paxton announces ongoing investigation into Carnival over data breach